Adding Carfilzomib Improved Health-Related QoL for Multiple Myeloma Patients

The addition of carfilzomib to lenalidomide and dexamethasone improved health-related quality of life compared with treatment with lenalidomide/dexamethasone alone among patients with relapsed multiple myeloma enrolled in the ASPIRE trial.

Source: CancerNetwork - September 7, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news